Understanding Colon Dysplasia in Inflammatory Bowel Disease (IBD)

Colon dysplasia is often discovered and removed during routine colon‑cancer screening. Inflammatory bowel disease (IBD) is a well‑documented risk factor for developing dysplasia in the colon.

Dysplasia itself produces no symptoms and does not mean cancer is inevitable. It simply indicates that some cells have the potential to become malignant. Prompt removal and a clear discussion with your gastroenterologist are essential.

Physicians diagnose colon dysplasia primarily through endoscopic examinations. The most common methods are:

• Colonoscopy: A flexible tube with a tiny camera is gently inserted through the anus to visualise the entire colon and rectum.
• Flexible sigmoidoscopy: A slimmer tube with a camera examines the distal one‑third of the colon.

During these procedures the abnormal area is usually removed. If only a single focus of low‑grade dysplasia is found, additional treatment is rarely required, but regular surveillance colonoscopies are advised to detect any new lesions early.

When multiple areas of dysplasia or high‑grade dysplasia are identified, the gastroenterology team may recommend more extensive surgery, such as a bowel resection, to eliminate the at‑risk tissue.

Dysplasia is classified as precancerous—it is not cancer and cannot spread, but it signals an increased future risk. Understanding the grade (low vs. high), number, and location of dysplastic lesions helps guide both treatment and long‑term IBD management.

Follow‑up scheduling is tailored to the individual. The first surveillance colonoscopy after a dysplasia diagnosis is typically performed within 3–6 months. If that exam shows no dysplasia, most clinicians schedule the next colonoscopy about 12 months later, adjusting the interval based on the severity of the previous findings and any additional cancer risk factors.

Dysplasia grading:

• Low‑grade dysplasia: Cells show early abnormal changes; removal during the initial endoscopy is often curative.
• High‑grade dysplasia: Cells appear more like cancer under the microscope and may warrant surgical intervention.

In most cases, endoscopic removal is sufficient treatment. A subset of patients, however, will require more complex surgery and a stricter surveillance schedule.

For individuals with IBD, especially those who have experienced symptoms for 8–10 years, expert guidelines recommend colonoscopic surveillance every 6–12 months to minimise the chance of progression to colon cancer.

In summary, colon dysplasia linked to IBD is usually detected during colonoscopy, can often be removed during the same procedure, and requires a personalized surveillance plan to protect long‑term health.